Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment

Mounting evidence demonstrates that CD8(+)CD122(+) T cells have suppressive properties with the capacity to inhibit T cell responses. Therefore, these cells are rational targets for cancer immunotherapy. Here, we demonstrate that CD122 monoclonal antibody (mAb; aCD122) therapy significantly suppress...

Descripción completa

Detalles Bibliográficos
Autores principales: Villarreal, Daniel O., Allegrezza, Michael J., Smith, Melissa A., Chin, Diana, Luistro, Leopoldo L., Snyder, Linda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752510/
https://www.ncbi.nlm.nih.gov/pubmed/29312597
http://dx.doi.org/10.18632/oncotarget.22642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752510/
https://www.ncbi.nlm.nih.gov/pubmed/29312597
http://dx.doi.org/10.18632/oncotarget.22642

Ejemplares similares